Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $45,086.72 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the completion of the sale, the chief executive officer now owns 293,367 shares in the company, valued at approximately $3,473,465.28. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $11.42 on Friday. The stock has a fifty day moving average price of $11.97 and a 200 day moving average price of $10.45. The stock has a market cap of $567.76 million, a PE ratio of -3.14 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its holdings in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after acquiring an additional 1,762 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on KALV shares. Jones Trading restated a “buy” rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).